The advent of immune checkpoint inhibitors (ICIs), particularly those targeting the PD-1/PD-L1 axis, has revolutionized the management of various malignancies, including non-small cell lung cancer (NSCLC) and melanoma. Here, CD274 is linked to non-small cell lung carcinoma.